Evidence map›Paper›PMID 40301030›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Successful Salvage Therapy with Pomalidomide, Cyclophosphamide, and Dexamethasone for IgM Myeloma with t (11;14) and Dim CD38 Expression Refractory to Daratumumab, Lenalidomide, and Dexamethasone.

Takashi Fujishima, Takahiro Kobayashi, Isuzu Kobayashi, Akihiro Kitadate, Yoshihiro Kameoka, Naoto Takahashi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Takashi FujishimaDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan.
Takahiro KobayashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan.
Isuzu KobayashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan.
Akihiro KitadateDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan.
Yoshihiro KameokaDepartment of Hematology, Akita Red Cross Hospital, Japan.
Naoto TakahashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein present the case of a 73-year-old man with IgM multiple myeloma (IgM-MM) and t(11;14). The tumor cells showed a small lymphoplasmacytic morphology and dim expression of CD38 and CD138. The MYD 88

Indexed as

ADP-ribosyl Cyclase 1Antineoplastic Combined Chemotherapy ProtocolsMembrane GlycoproteinsMultiple MyelomaSalvage TherapyAgedAntibodies, MonoclonalChromosomes, Human, Pair 11Chromosomes, Human, Pair 14CyclophosphamideDexamethasoneHumansImmunoglobulin MLenalidomideMaleThalidomideADP-ribosyl Cyclase 1Antibodies, MonoclonalCD38 protein, humanCyclophosphamidedaratumumabDexamethasoneImmunoglobulin MLenalidomideMembrane GlycoproteinspomalidomideThalidomideCD38daratumumabIgM myelomalenalidomidepomalidomidet(11;14)

Identifiers

PMID40301030
PMCPMC12589178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.